SKIP TO CONTENT

Riding the Celtic Tiger

As he walked into work on a rainy Thursday morning, John Dooley felt cheerful despite the bleak weather. BioSol, the global biotechnology corporation he worked for, had recently made significant progress in its therapeutic antibody for the treatment of adult and juvenile asthma. If the momentum continued, it would mean great things not only for the company but also for the thousands of people who suffered from the illness. On a personal level, John’s own career could get a real boost as well. Hadn’t his boss, Niall Doyle, said as much yesterday, when he told John that corporate headquarters was impressed and suggested they meet today to talk about future plans?

A version of this article appeared in the November 2005 issue of Harvard Business Review.

Partner Center